Skip to main content

Vprašanja in odgovori o cepljenju proti covidu-19 v EU

Click on each theme to find relevant questions and answers on COVID-19 vaccination in the EU, vaccine negotiations and its authorisation process.

You can also click on the questions you are interested in to find out more about the topic.

COVID-19 vaccination in the EU

Vaccine negotiations

Timeline - Vaccines authorisation

  1. 10 November 2021

    Commission approves APA with Valneva (purchase of up to 27 million doses in 2022, with an option for 33 million additional vaccines in 2023)

  2. 4 August 2021

    Commission approves APA with Novavax (purchase of up to 100 million doses, with an option for 100 million additional doses over the course of 2021, 2022, and 2023)

  3. 20 May 2021

    Commission signs a third contract with the pharmaceutical companies BioNTech and Pfizer, reserving an additional 1.8 billion doses on behalf of all EU Member States, between end-2021 to 2023

  4. 12 January 2021

    Conclusion exploratory talks with Valneva (30 million doses, plus option of 30 million additional doses)

  5. 18 January 2021

    Proposal to purchase an additional 200 million doses of the BioNTech Pfizer vaccine (with the option to acquire another 100 million doses)

  6. 17 November 2020

    Conclusion of exploratory talks with Novavax (100 million doses, plus option of 100 million additional doses)

  7. 15 November 2020

    Commission adopts decision to exercise option of up to 100 million additional doses (BioNTech Pfizer) and 80 million additional doses (Moderna)

  8. 4 December 2020

    Entry into force of the APA with Moderna

  9. 30 November 2020

    Entry into force of the APA with CureVac

  10. 25 November 2020

    Commission approves APA with Moderna (purchase of 80 million doses, plus an option for a further 80 million doses)

  11. 20 November 2020

    Entry into force of the APA with BioNTech Pfizer

  12. 19 November 2020

    Commission approves the APA with CureVac (purchase of 225 million doses, plus an option for a further 180 million doses)

  13. 11 November 2020

    Commission approves the APA with BioNTech Pfizer (purchase of 200 million doses, plus an option to request up to a further 100 million doses)

  14. 21 October 2020

    Entry into force of the APA with Johnson & Johnson

  15. 8 October 2020

    Commission approves APA with Johnson & Johnson (purchase of vaccines for 200 million people, and option for an additional 200 million people)

  16. 18 September 2020

    Entry into force of the APA with Sanofi-GSK (option to purchase up to 300 million doses of the Sanofi-GSK vaccine)

  17. 9 September 2020

    Conclusion of exploratory talks with BioNTech Pfizer

  18. 27 August 2020

    Entry into force of the APA with AstraZeneca

  19. 24 August 2020

    Conclusion of exploratory talks with Moderna

  20. 20 August 2020

    Conclusion of exploratory talks with CureVac

  21. 14 August 2020

    Commission approves APA (Advanced Purchasing Agreement) with AstraZeneca (for the purchase of 300 million doses of the vaccine, with an option to purchase 100 million more)

  22. 13 August 2020

    Conclusion of the exploratory talks with Johnson & Johnson

  23. 31 July 2020

    Conclusion of the exploratory talks with Sanofi-GSK

  24. 17 June 2020

    Adoption of the EU Vaccines Strategy 

    Start of negotiations with all six companies 

  25. 11 June 2020

    European Investment Bank (EIB) and BioNTech conclude a €100 million debt financing agreement to support the company´s vaccine programme and to expand the firm´s manufacturing capacity. 

Authorisation process of COVID-19 vaccines

Export transparency